Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
What You Missed On Wall Street This Morning » 12:08
09/23/22
09/23
12:08
09/23/22
12:08
FDX

FedEx

$150.55 /

-3.75 (-2.43%)

, COST

Costco

$473.00 /

-14.2 (-2.91%)

, FRPT

Freshpet

$46.30 /

+0.8 (+1.76%)

, SCHL

Scholastic

$36.06 /

-4.33 (-10.72%)

, BA

Boeing

$130.85 /

-7.75 (-5.59%)

, FUBO

FuboTV

$4.14 /

+0.2201 (+5.61%)

, ALLY

Ally Financial

$29.34 /

-1.34 (-4.37%)

, SPRO

Spero Therapeutics

$2.06 /

-0.135 (-6.16%)

, GSK

GSK

$29.19 /

-0.82 (-2.73%)

, EVR

Evercore

$81.16 /

-5.75 (-6.62%)

, MC

Moelis

$34.44 /

-2.615 (-7.06%)

, APO

Apollo Global

$49.22 /

-2.315 (-4.49%)

, HNHPF

Hon Hai Precision

$6.67 /

+0.061 (+0.92%)

, MRNA

Moderna

$122.01 /

-2.26 (-1.82%)

, AMZN

Amazon.com

$114.39 /

-2.91 (-2.48%)

, META

Meta Platforms

$140.52 /

-2.3 (-1.61%)

, AAPL

Apple

$150.33 /

-2.36 (-1.55%)

, PEP

PepsiCo

$167.87 /

-0.72 (-0.43%)

, DSKE

Daseke

$4.84 /

-0.24 (-4.72%)

, IBEX

Ibex

$16.29 /

+0.39 (+2.45%)

, APEI

American Public Education

$9.33 /

+1 (+12.00%)

, FLUX

Flux Power

$2.88 /

+0.35 (+13.83%)

, AIR

AAR Corp.

$34.22 /

-4.06 (-10.61%)

, CANO

Cano Health

$8.73 /

+0.38 (+4.55%)

, HUMA

Humacyte

$3.39 /

-0.215 (-5.96%)

, CS

Credit Suisse

$4.11 /

-0.59 (-12.55%)

, APA

APA Corp.

$33.05 /

-4.055 (-10.93%)

, TELL

Tellurian

$2.21 /

-0.555 (-20.11%)

, MDGS

Medigus

/

+

Get caught up quickly on…

ShowHide Related Items >><<
TELL Tellurian
$2.21 /

-0.555 (-20.11%)

SPRO Spero Therapeutics
$2.06 /

-0.135 (-6.16%)

SCHL Scholastic
$36.06 /

-4.33 (-10.72%)

PEP PepsiCo
$167.87 /

-0.72 (-0.43%)

MRNA Moderna
$122.01 /

-2.26 (-1.82%)

META Meta Platforms
$140.52 /

-2.3 (-1.61%)

MDGS Medigus
/

+

IBEX Ibex
$16.29 /

+0.39 (+2.45%)

HUMA Humacyte
$3.39 /

-0.215 (-5.96%)

HNHPF Hon Hai Precision
$6.67 /

+0.061 (+0.92%)

GSK GSK
$29.19 /

-0.82 (-2.73%)

FUBO FuboTV
$4.14 /

+0.2201 (+5.61%)

FRPT Freshpet
$46.30 /

+0.8 (+1.76%)

FLUX Flux Power
$2.88 /

+0.35 (+13.83%)

FDX FedEx
$150.55 /

-3.75 (-2.43%)

EVR Evercore
$81.16 /

-5.75 (-6.62%)

DSKE Daseke
$4.84 /

-0.24 (-4.72%)

CS Credit Suisse
$4.11 /

-0.59 (-12.55%)

COST Costco
$473.00 /

-14.2 (-2.91%)

CANO Cano Health
$8.73 /

+0.38 (+4.55%)

BA Boeing
$130.85 /

-7.75 (-5.59%)

APO Apollo Global
$49.22 /

-2.315 (-4.49%)

APEI American Public Education
$9.33 /

+1 (+12.00%)

APA APA Corp.
$33.05 /

-4.055 (-10.93%)

AMZN Amazon.com
$114.39 /

-2.91 (-2.48%)

ALLY Ally Financial
$29.34 /

-1.34 (-4.37%)

AIR AAR Corp.
$34.22 /

-4.06 (-10.61%)

AAPL Apple
$150.33 /

-2.36 (-1.55%)

FDX FedEx
$150.55 /

-3.75 (-2.43%)

09/23/22 Evercore ISI
FedEx target lowered, removed from Tactical Underperform list at Evercore ISI
09/23/22 Deutsche Bank
FedEx price target lowered to $190 from $320 at Deutsche Bank
09/23/22 Cowen
FedEx price target lowered to $185 from $230 at Cowen
09/23/22 UBS
FedEx price target lowered to $215 from $232 at UBS
COST Costco
$473.00 /

-14.2 (-2.91%)

09/23/22 Truist
Costco price target lowered to $559 from $571 at Truist
09/23/22 Evercore ISI
Costco price target lowered to $550 from $600 at Evercore ISI
09/23/22 DA Davidson
Costco price target raised to $455 from $440 at DA Davidson
09/23/22 MKM Partners
Costco price target lowered to $512 from $517 at MKM Partners
FRPT Freshpet
$46.30 /

+0.8 (+1.76%)

09/08/22 Truist
Truist downgrades Freshpet to Hold on updated EBITDA outlook and marketing cuts
09/08/22 Cowen
Freshpet price target lowered to $97 from $118 at Cowen
09/08/22 Baird
Freshpet price target lowered to $70 from $90 at Baird
09/08/22 Credit Suisse
Freshpet price target lowered to $50 from $65 at Credit Suisse
SCHL Scholastic
$36.06 /

-4.33 (-10.72%)

BA Boeing
$130.85 /

-7.75 (-5.59%)

09/23/22 BofA
Losing Xiamen to Airbus another setback for Boeing, says BofA
09/14/22 Jefferies
Woodward downgraded to Hold from Buy at Jefferies
09/08/22 Morgan Stanley
Boeing price target raised to $233 from $215 at Morgan Stanley
09/07/22 BofA
BofA raises target on 'fallen angel' Boeing, stays Neutral
FUBO FuboTV
$4.14 /

+0.2201 (+5.61%)

09/23/22 Wedbush
FuboTV upgraded to Outperform from Neutral at Wedbush
09/23/22 Wedbush
FuboTV upgraded to Outperform from Neutral at Wedbush
08/18/22 Needham
FuboTV price target raised to $7 from $5 at Needham
08/17/22 Evercore ISI
FuboTV price target raised to $8 from $5 at Evercore ISI
ALLY Ally Financial
$29.34 /

-1.34 (-4.37%)

09/23/22 Wells Fargo
Ally Financial downgraded to Equal Weight from Overweight at Wells Fargo
09/23/22 Wells Fargo
Ally Financial downgraded to Equal Weight from Overweight at Wells Fargo
09/15/22 Barclays
Ally Financial price target lowered to $49 from $56 at Barclays
07/25/22 Piper Sandler
Ally Financial downgraded to Underweight from Neutral at Piper Sandler
SPRO Spero Therapeutics
$2.06 /

-0.135 (-6.16%)

09/22/22 Evercore ISI
Evercore upgrades Spero, quadruples target on GSK partnership
09/22/22 Evercore ISI
Spero Therapeutics upgraded to Outperform from In Line at Evercore ISI
08/15/22 H.C. Wainwright
Spero Therapeutics price target lowered to $7 from $10 at H.C. Wainwright
05/23/22 H.C. Wainwright
Spero Therapeutics price target lowered to $10 from $37 at H.C. Wainwright
GSK GSK
$29.19 /

-0.82 (-2.73%)

09/15/22 Credit Suisse
GSK upgraded to Neutral from Underperform at Credit Suisse
09/13/22 Truist
AnaptysBio cut to Hold at Truist with price target of $28
09/08/22 Jefferies
GSK downgraded to Hold from Buy at Jefferies
EVR Evercore
$81.16 /

-5.75 (-6.62%)

09/23/22 UBS
Evercore downgraded to Sell from Neutral at UBS
07/18/22 Morgan Stanley
Evercore price target lowered to $97 from $136 at Morgan Stanley
07/08/22 Piper Sandler
Evercore price target lowered to $118 from $142 at Piper Sandler
04/07/22 Piper Sandler
Evercore price target lowered to $142 from $161 at Piper Sandler
MC Moelis
$34.44 /

-2.615 (-7.06%)

09/23/22 UBS
Moelis downgraded to Sell from Neutral at UBS
07/18/22 Morgan Stanley
Moelis downgraded to Underweight from Equal Weight at Morgan Stanley
07/11/22 Wolfe Research
Moelis downgraded to Underperform from Peer Perform at Wolfe Research
07/08/22 Piper Sandler
Moelis price target lowered to $45 from $50 at Piper Sandler
APO Apollo Global
$49.22 /

-2.315 (-4.49%)

09/23/22 BofA
Apollo Global upgraded to Neutral at BofA on more attractive valuation
09/23/22 BofA
Apollo Global upgraded to Neutral from Underperform at BofA
08/31/22 Barclays
Apollo Global initiated with an Overweight at Barclays
08/12/22 Deutsche Bank
Apollo Global price target lowered to $87 from $91 at Deutsche Bank
HNHPF Hon Hai Precision
$6.67 /

+0.061 (+0.92%)

03/14/22 BofA
Apple exposure to Shenzhen and Suzhou 'manageable,' says BofA
11/12/21 R.F. Lafferty
R.F. Lafferty upgrades Lordstown to Hold on better odds for Endurance production
MRNA Moderna
$122.01 /

-2.26 (-1.82%)

09/14/22 Argus
Moderna price target lowered to $150 from $180 at Argus
09/07/22 Deutsche Bank
Moderna upgraded to Buy with $165 target at Deutsche Bank
09/07/22 Deutsche Bank
Moderna upgraded to Buy from Hold at Deutsche Bank
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
AMZN Amazon.com
$114.39 /

-2.91 (-2.48%)

09/22/22 Northland
Amazon TNF kickoff scores 'a win' for Edgio, says Northland
09/20/22 Morgan Stanley
Shopify price target lowered to $40 from $44 at Morgan Stanley
09/20/22 Piper Sandler
Change Healthcare downgraded to Neutral from Overweight at Piper Sandler
09/14/22 Oppenheimer
TNF sponsorship key step to generating higher SGP adoption, says Oppenheimer
META Meta Platforms
$140.52 /

-2.3 (-1.61%)

09/13/22 Morgan Stanley
Total U.S. time spent on Meta down 3% year/year in August, says Morgan Stanley
09/12/22 Piper Sandler
Meta Platforms price target lowered to $175 from $190 at Piper Sandler
08/22/22 Loop Capital
Meta Platforms price target lowered to $165 from $180 at Loop Capital
08/22/22 Loop Capital
Enovix price target raised to $100 from $50 at Loop Capital
AAPL Apple
$150.33 /

-2.36 (-1.55%)

09/21/22 BofA
Carrier promotions give Apple iPhone users impetus to upgrade, says BofA
09/20/22 Evercore ISI
Apple price target raised to $190 at Evercore ISI after survey of iPhone buyers
09/14/22 Bernstein
Bernstein models Apple iPhone revenues down 3%-4% in FY23
09/13/22 Evercore ISI
Apple iPhone delivery data points to robust demand, says Evercore ISI
PEP PepsiCo
$167.87 /

-0.72 (-0.43%)

08/22/22 Morgan Stanley
Topline momentum building at PepsiCo, says Morgan Stanley
08/19/22 Jefferies
Jefferies concerned about potential Keurig acquisition of Vital
08/02/22 Stifel
Celsius Holdings price target raised to $115 from $93 at Stifel
08/02/22 B. Riley
Celsius Holdings price target raised to $112 from $100 at B. Riley
DSKE Daseke
$4.84 /

-0.24 (-4.72%)

07/28/22 Stifel
Daseke upgraded to Buy from Hold at Stifel
01/06/22 Northland
Daseke named a top pick for 2022 at Northland
IBEX Ibex
$16.29 /

+0.39 (+2.45%)

09/23/22 Piper Sandler
Ibex price target lowered to $20 from $21 at Piper Sandler
07/19/22 Citi
Ibex assumed with Neutral from Buy at Citi
07/18/22 Piper Sandler
Ibex price target raised to $21 from $17 at Piper Sandler
06/08/22
Baird to hold a conference
APEI American Public Education
$9.33 /

+1 (+12.00%)

08/11/22 Truist
American Public Education price target lowered to $16 from $21 at Truist
08/10/22 Barrington
American Public Education price target lowered to $15 from $20 at Barrington
05/12/22 Truist
American Public Education price target lowered to $21 from $26 at Truist
05/11/22 Barrington
American Public Education price target lowered to $20 from $25 at Barrington
FLUX Flux Power
$2.88 /

+0.35 (+13.83%)

02/11/22 Maxim
Flux Power price target lowered to $8 from $13 at Maxim
10/05/21 H.C. Wainwright
Flux Power initiated with a Buy at H.C. Wainwright
09/28/21 Maxim
Flux Power price target lowered to $13 from $15 at Maxim
AIR AAR Corp.
$34.22 /

-4.06 (-10.61%)

09/23/22 Truist
AAR Corp. price target lowered to $48 from $54 at Truist
07/19/22 Truist
AAR Corp. price target lowered to $54 from $58 at Truist
03/23/22 RBC Capital
AAR Corp. price target raised to $56 from $50 at RBC Capital
03/23/22 Truist
AAR Corp. price target raised to $58 from $53 at Truist
CANO Cano Health
$8.73 /

+0.38 (+4.55%)

09/23/22 Citi
Cano Health could be worth $14 per share in buyout, says Citi
09/07/22 Truist
Cano Health initiated with a Hold at Truist
08/10/22 Citi
Cano Health price target lowered to $7 from $8 at Citi
07/21/22 Stifel
Logical to see Oak Street, Cano as 'in play' after 1Life deal, says Stifel
HUMA Humacyte
$3.39 /

-0.215 (-5.96%)

08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
CS Credit Suisse
$4.11 /

-0.59 (-12.55%)

09/21/22 RBC Capital
Credit Suisse price target raised to CHF 6.60 from CHF 6 at RBC Capital
08/31/22 Deutsche Bank
Credit Suisse price target lowered to CHF 6 from CHF 7 at Deutsche Bank
08/03/22 Berenberg
Credit Suisse price target lowered to CHF 7 from CHF 8 at Berenberg
08/02/22 Goldman Sachs
Credit Suisse downgraded to Sell from Neutral at Goldman Sachs
APA APA Corp.
$33.05 /

-4.055 (-10.93%)

09/19/22 Truist
APA Corp. price target raised to $75 from $66 at Truist
09/12/22 Citi
Citi opens '90-day Catalyst Watch' in APA into well results
09/12/22 Citi
APA Corp. upgraded to Buy from Neutral at Citi
08/31/22 Barclays
APA Corp. price target lowered to $53 from $55 at Barclays
TELL Tellurian
$2.21 /

-0.555 (-20.11%)

08/09/22 BofA
Tellurian upgraded to Buy at BofA on natural gas tailwinds
08/09/22 BofA
Tellurian upgraded to Buy from Neutral at BofA
08/01/22 Evercore ISI
Tellurian downgraded to In Line from Outperform at Evercore ISI
08/01/22 Evercore ISI
Tellurian downgraded to In Line from Outperform at Evercore ISI
MDGS Medigus
/

+

TELL Tellurian
$2.21 /

-0.555 (-20.11%)

SPRO Spero Therapeutics
$2.06 /

-0.135 (-6.16%)

SCHL Scholastic
$36.06 /

-4.33 (-10.72%)

PEP PepsiCo
$167.87 /

-0.72 (-0.43%)

MRNA Moderna
$122.01 /

-2.26 (-1.82%)

META Meta Platforms
$140.52 /

-2.3 (-1.61%)

MDGS Medigus
/

+

MC Moelis
$34.44 /

-2.615 (-7.06%)

IBEX Ibex
$16.29 /

+0.39 (+2.45%)

HUMA Humacyte
$3.39 /

-0.215 (-5.96%)

GSK GSK
$29.19 /

-0.82 (-2.73%)

FUBO FuboTV
$4.14 /

+0.2201 (+5.61%)

FRPT Freshpet
$46.30 /

+0.8 (+1.76%)

FLUX Flux Power
$2.88 /

+0.35 (+13.83%)

FDX FedEx
$150.55 /

-3.75 (-2.43%)

EVR Evercore
$81.16 /

-5.75 (-6.62%)

DSKE Daseke
$4.84 /

-0.24 (-4.72%)

CS Credit Suisse
$4.11 /

-0.59 (-12.55%)

COST Costco
$473.00 /

-14.2 (-2.91%)

CANO Cano Health
$8.73 /

+0.38 (+4.55%)

BA Boeing
$130.85 /

-7.75 (-5.59%)

APO Apollo Global
$49.22 /

-2.315 (-4.49%)

APEI American Public Education
$9.33 /

+1 (+12.00%)

APA APA Corp.
$33.05 /

-4.055 (-10.93%)

AMZN Amazon.com
$114.39 /

-2.91 (-2.48%)

ALLY Ally Financial
$29.34 /

-1.34 (-4.37%)

AIR AAR Corp.
$34.22 /

-4.06 (-10.61%)

AAPL Apple
$150.33 /

-2.36 (-1.55%)

  • 04
    May
PEP PepsiCo
$167.87 /

-0.72 (-0.43%)

MRNA Moderna
$122.01 /

-2.26 (-1.82%)

META Meta Platforms
$140.52 /

-2.3 (-1.61%)

MC Moelis
$34.44 /

-2.615 (-7.06%)

HNHPF Hon Hai Precision
$6.67 /

+0.061 (+0.92%)

GSK GSK
$29.19 /

-0.82 (-2.73%)

FRPT Freshpet
$46.30 /

+0.8 (+1.76%)

FDX FedEx
$150.55 /

-3.75 (-2.43%)

CS Credit Suisse
$4.11 /

-0.59 (-12.55%)

COST Costco
$473.00 /

-14.2 (-2.91%)

CANO Cano Health
$8.73 /

+0.38 (+4.55%)

BA Boeing
$130.85 /

-7.75 (-5.59%)

APO Apollo Global
$49.22 /

-2.315 (-4.49%)

AMZN Amazon.com
$114.39 /

-2.91 (-2.48%)

ALLY Ally Financial
$29.34 /

-1.34 (-4.37%)

AAPL Apple
$150.33 /

-2.36 (-1.55%)

TELL Tellurian
$2.21 /

-0.555 (-20.11%)

SPRO Spero Therapeutics
$2.06 /

-0.135 (-6.16%)

PEP PepsiCo
$167.87 /

-0.72 (-0.43%)

MRNA Moderna
$122.01 /

-2.26 (-1.82%)

META Meta Platforms
$140.52 /

-2.3 (-1.61%)

MDGS Medigus
/

+

MC Moelis
$34.44 /

-2.615 (-7.06%)

HUMA Humacyte
$3.39 /

-0.215 (-5.96%)

HNHPF Hon Hai Precision
$6.67 /

+0.061 (+0.92%)

GSK GSK
$29.19 /

-0.82 (-2.73%)

FUBO FuboTV
$4.14 /

+0.2201 (+5.61%)

FRPT Freshpet
$46.30 /

+0.8 (+1.76%)

FLUX Flux Power
$2.88 /

+0.35 (+13.83%)

FDX FedEx
$150.55 /

-3.75 (-2.43%)

CS Credit Suisse
$4.11 /

-0.59 (-12.55%)

COST Costco
$473.00 /

-14.2 (-2.91%)

CANO Cano Health
$8.73 /

+0.38 (+4.55%)

BA Boeing
$130.85 /

-7.75 (-5.59%)

APO Apollo Global
$49.22 /

-2.315 (-4.49%)

APA APA Corp.
$33.05 /

-4.055 (-10.93%)

AMZN Amazon.com
$114.39 /

-2.91 (-2.48%)

ALLY Ally Financial
$29.34 /

-1.34 (-4.37%)

AAPL Apple
$150.33 /

-2.36 (-1.55%)

TELL Tellurian
$2.21 /

-0.555 (-20.11%)

PEP PepsiCo
$167.87 /

-0.72 (-0.43%)

MRNA Moderna
$122.01 /

-2.26 (-1.82%)

META Meta Platforms
$140.52 /

-2.3 (-1.61%)

GSK GSK
$29.19 /

-0.82 (-2.73%)

FUBO FuboTV
$4.14 /

+0.2201 (+5.61%)

FDX FedEx
$150.55 /

-3.75 (-2.43%)

CS Credit Suisse
$4.11 /

-0.59 (-12.55%)

COST Costco
$473.00 /

-14.2 (-2.91%)

CANO Cano Health
$8.73 /

+0.38 (+4.55%)

BA Boeing
$130.85 /

-7.75 (-5.59%)

APO Apollo Global
$49.22 /

-2.315 (-4.49%)

APA APA Corp.
$33.05 /

-4.055 (-10.93%)

AMZN Amazon.com
$114.39 /

-2.91 (-2.48%)

ALLY Ally Financial
$29.34 /

-1.34 (-4.37%)

AAPL Apple
$150.33 /

-2.36 (-1.55%)

Earnings
Humacyte announces presentations by Ukrainian surgeons on use of HAV » 08:06
09/23/22
09/23
08:06
09/23/22
08:06
HUMA

Humacyte

$3.61 /

-0.045 (-1.23%)

Humacyte announced the…

Humacyte announced the presentation of a clinical update on the Human Acellular Vessel, HAV, for the treatment of vascular trauma. The update was presented by Ukrainian surgeon collaborators, Oleksandr Sokolov, M.D., Ph.D. and Vasyl Shaprynskyi, M.D., Ph.D., at the 36th European Society for Vascular Surgery, ESVS, Annual Meeting in Rome, Italy taking place from September 20-23, 2022. Humacyte's investigational HAV is designed to offer off-the-shelf availability and resistance to infection and to address long-standing limitations in vascular tissue repair and replacement. Dr. Shaprynskyi attended the conference in-person and presented a live talk entitled, "The First Experience of Using the Human Acellular Vessels in Ukraine for the Treatment of Patients with Vascular Trauma," while Dr. Sokolov spoke virtually from Ukraine and presented, "Vascular Trauma Due to Blast Injury. Experience of Dnipro in Russian-Ukrainian War 2022." Drs. Shaprynskyi and Sokolov reported that surgeons in Ukraine have utilized the HAV to treat patients with a multitude of wartime injuries. Dr. Sokolov provided a clinical update on a patient with a blast injury to the shoulder who received a repair using the HAV. The patient is now beyond three-month follow up without complication. Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte, added, "As we progress in our humanitarian efforts with the HAV, being able to witness these firsthand patient cases from surgeons in Ukraine is a powerful experience. We set out to develop engineered replacement vessels that are durable, infection-resistant and off-the-shelf to address long-standing limitations in vessel repair, both for civilians and for military personnel. Given our existing designation as a Priority Product from the U.S. Department of Defense, it is gratifying to see that the HAV is helping patients suffering from wartime injuries in Ukraine right now."

ShowHide Related Items >><<
HUMA Humacyte
$3.61 /

-0.045 (-1.23%)

HUMA Humacyte
$3.61 /

-0.045 (-1.23%)

08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
HUMA Humacyte
$3.61 /

-0.045 (-1.23%)

HUMA Humacyte
$3.61 /

-0.045 (-1.23%)

Hot Stocks
Humacyte expands board of directors, leadership team with new appointments » 08:03
09/20/22
09/20
08:03
09/20/22
08:03
HUMA

Humacyte

$3.74 /

-0.21 (-5.32%)

Humacyte announced the…

Humacyte announced the appointments of two healthcare professionals to the Company's Board of Directors and leadership team. Lt. General Bruce Green, M.D., USAF-ret., former Surgeon General of the U.S. Air Force, joins as a member of the Board of Directors. In addition, pharma industry veteran Yang Cao, Ph.D. joins as the Company's Chief Regulatory Officer. Current Chief Regulatory Officer, Bill Tente, will remain with Humacyte as an Executive Advisor, partnering on regulatory initiatives for the organization with Dr. Cao and team. General Green served as Assistant Surgeon General for Health Care Operations and Deputy Surgeon General, and was appointed Air Force Surgeon General in 2009. Prior to joining Humacyte, Dr. Cao served as Senior Vice President and Head of Regulatory Affairs and Quality Assurance at Ascentage Pharma.

ShowHide Related Items >><<
HUMA Humacyte
$3.74 /

-0.21 (-5.32%)

HUMA Humacyte
$3.74 /

-0.21 (-5.32%)

08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
HUMA Humacyte
$3.74 /

-0.21 (-5.32%)

HUMA Humacyte
$3.74 /

-0.21 (-5.32%)

Hot Stocks
Humacyte announces presentation on Human Acellular Vessel » 08:04
09/09/22
09/09
08:04
09/09/22
08:04
HUMA

Humacyte

$4.64 /

+0.365 (+8.54%)

Humacyte announced the…

Humacyte announced the presentation of a clinical update on the Human Acellular Vessel for the treatment of vascular trauma. The HAV is designed to offer off-the-shelf availability and resistance to infection, as well as to address long-standing limitations in vascular tissue repair and replacement. The update was presented by Todd E. Rasmussen, M.D., FACS, at the 44th International Committee of Military Medicine World Congress in Brussels, Belgium. Speaking to an audience of NATO and other international surgeons, Dr. Rasmussen reported that over the past several decades the incidence of wartime vascular injury has increased. Dr. Rasmussen added that vascular injury, whether in a military or civilian setting, is a leading cause of death and or amputation. Dr. Rasmussen's presentation highlighted the clinical progress of the HAV, including updates on his own experiences and those of his colleagues utilizing the vessel to treat patients, as well as the potential of the investigational product to overcome limitations in care. According to Dr. Rasmussen's conclusions, injured service members and those with certain complex injuries in the civilian sector could benefit from the use of a readily available and infection resistant vascular conduit that would facilitate quick implantation and restoration of blood flow, even in the setting of contaminated wounds such as those encountered on the battlefield. Humacyte's investigational HAVs were recently provided as part of a humanitarian relief effort to several front-line Ukrainian hospitals, allowing doctors the opportunity to utilize the HAVs to treat patients with traumatic vascular injuries during the conflict. Patients successfully treated to date under the humanitarian program include those with a range of traumatic injuries, including those from gunshots, shrapnel, and industrial accidents. Humacyte is working closely alongside the Office of International Programs within the U.S. Food and Drug Administration and the Ukrainian Ministry of Health as the humanitarian efforts in Ukraine progress, and the company continues to provide this additional treatment option to those affected.

ShowHide Related Items >><<
HUMA Humacyte
$4.64 /

+0.365 (+8.54%)

HUMA Humacyte
$4.64 /

+0.365 (+8.54%)

08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
HUMA Humacyte
$4.64 /

+0.365 (+8.54%)

HUMA Humacyte
$4.64 /

+0.365 (+8.54%)

Over a month ago
Syndicate
Humacyte files $300M mixed securities shelf  16:19
09/01/22
09/01
16:19
09/01/22
16:19
HUMA

Humacyte

$4.18 /

+0.52 (+14.21%)

 
ShowHide Related Items >><<
HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

Syndicate
Humacyte files to sell 89.72M shares of common stock for holders  16:17
09/01/22
09/01
16:17
09/01/22
16:17
HUMA

Humacyte

$4.18 /

+0.52 (+14.21%)

 
ShowHide Related Items >><<
HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

Syndicate
Humacyte files to sell 5.18M shares of common stock  16:17
09/01/22
09/01
16:17
09/01/22
16:17
HUMA

Humacyte

$4.18 /

+0.52 (+14.21%)

 
ShowHide Related Items >><<
HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

HUMA Humacyte
$4.18 /

+0.52 (+14.21%)

Recommendations
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler » 12:02
08/12/22
08/12
12:02
08/12/22
12:02
HUMA

Humacyte

$4.44 /

+0.06 (+1.37%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Humacyte to $3.50 from $4.00 and keeps an Underweight rating on the shares. While Humacyte did beat financial expectations for Q2, enrollment in the trauma and AV access studies were fairly modest over the past two plus months, and O'Brien would not be surprised to see the expected timing of approval slip a little, though not significantly, the analyst tells investors in a research note.

ShowHide Related Items >><<
HUMA Humacyte
$4.44 /

+0.06 (+1.37%)

HUMA Humacyte
$4.44 /

+0.06 (+1.37%)

07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
10/29/21 Cowen
Humacyte initiated with an Outperform at Cowen
HUMA Humacyte
$4.44 /

+0.06 (+1.37%)

HUMA Humacyte
$4.44 /

+0.06 (+1.37%)

Earnings
Humacyte reports Q2 EPS 35c, consensus (22c) » 07:03
08/12/22
08/12
07:03
08/12/22
07:03
HUMA

Humacyte

$4.38 /

+0.89 (+25.50%)

Reports Q2 revenue…

Reports Q2 revenue $1.301M, consensus $200,000. "Humacyte has continued to make great progress throughout the second quarter of 2022, advancing our lead candidate, the HAV, in both our clinical and preclinical programs as well as our humanitarian effort in Ukraine," said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. "We are thrilled that the HAVs implanted in several Ukrainian patients are reported to be functioning and infection-free, providing further real-world evidence of the potential of HAV treatment for trauma. In addition, we are pleased with the progress of our small-diameter HAV program which we believe continues to show promise in preclinical CABG models, and we look forward to continued advancement as we move toward the clinic. Finally, we welcome Dr. Diane Seimetz to our Board of Directors, and we are excited to leverage her regulatory and commercial expertise as we move through our late-stage vascular clinical programs and approach potential approval and commercialization of the HAV."

ShowHide Related Items >><<
HUMA Humacyte
$4.38 /

+0.89 (+25.50%)

HUMA Humacyte
$4.38 /

+0.89 (+25.50%)

07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
10/29/21 Cowen
Humacyte initiated with an Outperform at Cowen
HUMA Humacyte
$4.38 /

+0.89 (+25.50%)

HUMA Humacyte
$4.38 /

+0.89 (+25.50%)

Hot Stocks
Humacyte announces presentation of preclinical data on HAV » 08:04
07/19/22
07/19
08:04
07/19/22
08:04
HUMA

Humacyte

$3.39 /

-0.115 (-3.29%)

Humacyte announced that…

Humacyte announced that six-month outcomes from a preclinical study of a small diameter Human Acellular Vessel in coronary artery bypass grafting will be presented at the Basic Cardiovascular Sciences Scientific Sessions taking place in Chicago, IL July 25-28, 2022. Title: "Tissue-engineered Human Acellular Blood Vessels for Coronary Artery Bypass Grafting."

ShowHide Related Items >><<
HUMA Humacyte
$3.39 /

-0.115 (-3.29%)

HUMA Humacyte
$3.39 /

-0.115 (-3.29%)

07/18/22 BTIG
Humacyte price target lowered to $10 from $12 at BTIG
05/15/22 Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
03/29/22 Piper Sandler
Humacyte price target lowered to $10 from $17 at Piper Sandler
10/29/21 Cowen
Humacyte initiated with an Outperform at Cowen
HUMA Humacyte
$3.39 /

-0.115 (-3.29%)

HUMA Humacyte
$3.39 /

-0.115 (-3.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.